Elevation of the tumor mutational burden, enhanced antigen presentation and cellular immunity, and increased PD-L1 expression, are all correlated with the presence of ARID1A and ARID1B mutations; suggesting that mutated ARID1A and ARID1B could serve as novel biomarkers to predict sensitivity and prognosis to ICB in advanced NSCLC patients (55). The gene discussed is ARID1B; the disease is non-small cell lung carcinoma.